Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 878
- Registration Number
- NCT06627647
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT06624059
- Locations
- 🇦🇺
Royal North Shore Hospital, St. Leonards, New South Wales, Australia
🇦🇺Calvary Mater Newcastle, Waratah, New South Wales, Australia
🇨🇳Xiangya Hospital of Centre-South University, Changsha, China
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 680
- Registration Number
- NCT06623422
- Locations
- 🇺🇸
Providence St. Jude Medical Center ( Site 0106), Fullerton, California, United States
🇺🇸Ellis Fischel Cancer Center ( Site 0133), Columbia, Missouri, United States
🇺🇸Lake Regional Hospital-Cancer Center ( Site 0123), Osage Beach, Missouri, United States
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
- Conditions
- Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal CancerAdvanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 750
- Registration Number
- NCT06607185
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
- Conditions
- Metastatic Nonsmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Aetion, Inc.
- Target Recruit Count
- 851
- Registration Number
- NCT06607393
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
- Conditions
- Non-Small Cell Lung CancerAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06594874
- Locations
- 🇨🇳
Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, China
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- Aetion, Inc.
- Target Recruit Count
- 304
- Registration Number
- NCT06585189
LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 29
- Registration Number
- NCT06576635
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 660
- Registration Number
- NCT06564844
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1000
- Registration Number
- NCT06561386
- Locations
- 🇮🇹
Local Institution - 0222, Ravenna, Italy
🇺🇸Local Institution - 0368, Tucson, Arizona, United States
🇺🇸Local Institution - 0112, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.